Associated tags: Human, Animal, Boehringer Ingelheim, Animal Health, Pharmaceutical industry, Health, Patient, Research
Locations: SPAIN, DELAWARE, JAPAN, PENNSYLVANIA, UNITED STATES OF AMERICA, MASSACHUSETTS, ITALY, USA, BRAZIL, PHILADELPHIA, EUROPEAN UNION, EU, SWITZERLAND, CANADA, LONDON, GB, TOKYO, INGELHEIM AM RHEIN, DE, III, II, GERMANY, EUROPE, KENYA, UNITED STATES, GEORGIA
Science,
Corporate headquarters,
FDA,
Health equity,
Investment,
Liver disease,
Growth,
EUR,
Vaccine,
Tick,
Biomass,
DSM-IV codes,
Medicine,
Finance,
CRM,
Chronic kidney disease,
Executive officer,
Heart failure,
Paris Agreement,
Research and development,
Dog,
Capital expenditure,
Flea,
MASH,
Idiopathic pulmonary fibrosis,
Coccidioides immitis,
Stroke,
Acceleration,
Pet,
Health,
Diabetes,
Artificial intelligence,
Mental health,
EMA,
Notifiable disease,
Cancer,
Boehringer Ingelheim,
Phase II,
Pharma,
Cat,
Environment,
Patient,
Conditional sentence,
Boehringer,
Pharmaceutical industry Group net sales rose by 9.7%* to EUR 25.6 billion in 2023, driven by 10.3%* growth in Human Pharma and 6.9%* growth in Animal Health.
Key Points:
- Group net sales rose by 9.7%* to EUR 25.6 billion in 2023, driven by 10.3%* growth in Human Pharma and 6.9%* growth in Animal Health.
- “I am excited to see how balanced and healthy our pipeline looks today,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors.
- To support the company’s growth, Boehringer announced a 5-year, EUR 7 billion capital investment plan last year.
- For 2024, Boehringer Ingelheim expects a slight year-on-year increase in revenues on a comparable basis, adjusted for currency and extraordinary effects.
Technology,
Men,
LGBTQ+,
Professional Services,
DEI (Diversity, Equity and Inclusion),
Consumer,
Clinical Trials,
Diabetes,
Health,
Apps,
Applications,
Generation Z,
Generation X,
Other Consumer,
Mobile,
Wireless,
Baby Boomers,
Women,
Pharmaceutical,
Boehringer Ingelheim,
Heart,
Overweight,
Death,
Partnership,
Research,
Medicine,
Environment,
Obesity,
Senior,
Patient,
Multimedia,
Boehringer,
Clinical trial,
Pharmacy,
Pharmaceutical industry Walgreens and Boehringer Ingelheim today announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusive and equitable.
Key Points:
- Walgreens and Boehringer Ingelheim today announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusive and equitable.
- View the full release here: https://www.businesswire.com/news/home/20240502134064/en/
Through this collaboration, Boehringer Ingelheim will leverage select Walgreens community pharmacies as clinical trial sites for people living with obesity, overweight and type 2 diabetes.
- “Embracing our pharmacy clinical trial centers in this study underscores our joint commitment to community health and innovation,” said Ramita Tandon, Chief Clinical Trials Officer at Walgreens.
- “Boehringer is proud to embrace this community-centric approach to clinical research with Walgreens and EmVenio,” said Lennart Jungersten, Senior Vice President, Medicine & Regulatory Affairs at Boehringer Ingelheim U.S. “By bringing clinical trials into the heart of local communities, we’re making them more accessible, helping to provide access to diverse populations with pressing health needs to participate in our clinical trials.
Arthralgia,
Urinary tract infection,
Uncertainty,
Human,
NMPA,
Psoriasis,
Disease,
Multiple organ dysfunction syndrome,
Incidence,
Risk,
GPP,
Boehringer Ingelheim,
Patient,
Ageing,
Executive officer,
Immunoglobulin G,
Anxiety,
Doctor of Philosophy,
MD,
Quality of life,
Flare,
Injection site reaction,
Clinical trial,
Skin,
Fever,
Immune system,
Pain,
Itch,
Food,
FDA,
Yale University,
Fear In the trial with 123 patients, no flares were observed after week 4 of SPEVIGO® subcutaneous treatment in the high-dose group (n=30).13,14,15,16 In the Effisayil® 2 trial, SPEVIGO® was associated with an increased incidence (≥9 cases per 100 patient-years) of injection site reaction, urinary tract infection, arthralgia, and pruritus compared to placebo.
Key Points:
- In the trial with 123 patients, no flares were observed after week 4 of SPEVIGO® subcutaneous treatment in the high-dose group (n=30).13,14,15,16 In the Effisayil® 2 trial, SPEVIGO® was associated with an increased incidence (≥9 cases per 100 patient-years) of injection site reaction, urinary tract infection, arthralgia, and pruritus compared to placebo.
- “Until now, people living with GPP have not had any approved options to treat their disease,” said Bruce Strober, MD, PhD, Clinical Professor, Dermatology, Yale University and Central Connecticut Dermatology.
- “Experiencing GPP can be mentally and physically devastating, leaving those affected with uncertainty and fear of the next episode.
- Therefore, expanding the treatment of GPP is a critical step towards addressing patients’ needs.”
Health,
Atlanta Braves,
Partnership,
Boehringer Ingelheim,
Atlanta,
Truist Park,
Love,
Pet,
Animal,
Corporation,
Boehringer Ingelheim Animal Health,
Fine chemical DULUTH, Ga., April 4, 2024 /PRNewswire/ -- Boehringer Ingelheim, the largest animal health company in Georgia, is proud to announce its new partnership with the Atlanta Braves and the Atlanta Braves Foundation as the Official Animal Health Company partner, starting with the 2024 MLB season.
Key Points:
- DULUTH, Ga., April 4, 2024 /PRNewswire/ -- Boehringer Ingelheim, the largest animal health company in Georgia, is proud to announce its new partnership with the Atlanta Braves and the Atlanta Braves Foundation as the Official Animal Health Company partner, starting with the 2024 MLB season.
- Randolph Legg, President of Boehringer Ingelheim Animal Health USA, expressed his excitement about the partnership, "We are thrilled to join forces with the Atlanta Braves, a team that shares our commitment to community and excellence.
- Boehringer Ingelheim Animal Health has a significant presence in the United States, providing a wide range of products and services to improve the health and wellbeing of animals.
- Throughout the season, fans can expect multiple activations at the ballpark and in The Battery Atlanta, further strengthening the bond between the Atlanta Braves, Boehringer Ingelheim, and the community.
Parasitism,
Health,
DSM-IV codes,
Moxidectin,
Coccidioides immitis,
Boehringer Ingelheim,
Tablet,
Tick,
Diarrhea,
Dog,
Lethargy,
Boehringer,
Breeding,
Pet,
Vomiting,
Animal,
Pharmaceutical industry The Boehringer Ingelheim Cares Foundation has donated 1.9 million doses of NexGard® PLUS to animal shelters in need.
Key Points:
- The Boehringer Ingelheim Cares Foundation has donated 1.9 million doses of NexGard® PLUS to animal shelters in need.
- The Foundation has donated 1.9 million doses of NexGard® PLUS chews, a delicious beef-flavored soft chew, designed to protect dogs from fleas and ticks, prevent heartworm disease, and treat and control roundworms and hookworms.
- Over 6 million doses of NexGard® PLUS chews have been sold since its launch in 2023.
- NexGard® PLUS (afoxolaner, moxidectin, and pyrantel chewable tablets) are for use in dogs only.
GPR52,
Prefrontal cortex,
Attention,
Psychosis,
Boehringer Ingelheim,
Therapy,
GPCR,
Medicine,
Patient,
Hallucination,
Disease,
DSM-IV codes,
Brain,
Research,
Delusion,
Partnership,
Pharmaceutical industry While ‘positive’ symptoms can be stabilized with antipsychotics, some of which can have side effects, there are currently no approved medicines for ‘negative’ or cognitive symptoms.
Key Points:
- While ‘positive’ symptoms can be stabilized with antipsychotics, some of which can have side effects, there are currently no approved medicines for ‘negative’ or cognitive symptoms.
- The development of a new schizophrenia treatment targeting GPR52 has the potential to address all three aspects of schizophrenia1,2 providing a novel precision treatment.
- “We’re very excited to enter this partnership with Sosei Heptares with this novel approach, which aims to address a huge unmet need of those living with schizophrenia.
- We’re delighted to partner with Boehringer Ingelheim and leverage its leading expertise in neurological disease research and innovation.
Retrieved on:
Monday, February 26, 2024
Survodutide has the potential to become a best-in-class treatment for MASH, a liver disease connected with other cardiovascular, renal, and metabolic conditions.3,4,6
Key Points:
- Survodutide has the potential to become a best-in-class treatment for MASH, a liver disease connected with other cardiovascular, renal, and metabolic conditions.3,4,6
Survodutide is a glucagon/GLP-1 receptor dual agonist with a novel mechanism of action, and the first to show this level of benefit in a Phase II MASH trial.2,7 The glucagon agonist component in survodutide has the potential to increase energy expenditure,7and has a direct impact in the liver which potentially contributes to the improvement of fibrosis.2 The GLP-1 agonist component decreases appetite while increasing fullness and satiety.7,8
“I am thrilled to see these statistically significant results from the Phase II trial of survodutide in MASH and fibrosis.
- These data position survodutide as a potential leading treatment for a population with great unmet medical needs, and will bring hope to people living with MASH and with fibrosis,” said Dr. Arun Sanyal, M.D., Professor of Medicine, Physiology and Molecular Pathology at Virginia Commonwealth University School of Medicine, and Principal Investigator of the trial.
- “I am looking forward to sharing further detail on key secondary endpoints, including the percentage of adults who saw an improvement in fibrosis, at a congress in the first half of this year.”
“These MASH results show survodutide has potential to become a best-in-class treatment, and we believe its true differentiator is the action of the glucagon receptor agonism which works directly on the liver,” said Carinne Brouillon, Head of Human Pharma, Boehringer Ingelheim.
- “In order to bring this potential treatment to the more than 1 billion people affected by interconnected cardiovascular, renal, metabolic diseases, we will move forward as quickly as possible in MASH.
Retrieved on:
Monday, February 19, 2024
Veterinarian,
Doctor of Philosophy,
Livestock,
Artificial intelligence,
Boehringer,
Intelligence,
DVM,
Health,
Animal,
Farmer,
Limp,
Eye,
Horse,
Boehringer Ingelheim,
Smartphone,
Diagnosis,
Movement,
Human,
Boehringer Ingelheim Animal Health,
Gait,
Partnership,
Veterinary medicine A new global commercial partnership between Boehringer Ingelheim and Sleip will expand access to AI to enhance detection, diagnosis and treatment of lameness in horses.
Key Points:
- A new global commercial partnership between Boehringer Ingelheim and Sleip will expand access to AI to enhance detection, diagnosis and treatment of lameness in horses.
- This partnership delivers on the shared commitment of Boehringer and Sleip to deliver innovative solutions that help veterinary professionals continue to advance their profession and improve the care and wellbeing of horses.
- Changes in gait and signs of lameness can be less pronounced at first and difficult to detect.
- Through this collaboration, Boehringer will support the introduction of the pioneering Sleip app to the veterinary community, making this technology even more accessible.
RIDGEFIELD, Conn., March 7, 2024 /PRNewswire/ -- Boehringer Ingelheim today announced it will cap out-of-pocket costs at $35 per month for eligible patientsi for all the company's inhaler products.
Key Points:
- RIDGEFIELD, Conn., March 7, 2024 /PRNewswire/ -- Boehringer Ingelheim today announced it will cap out-of-pocket costs at $35 per month for eligible patientsi for all the company's inhaler products.
- Boehringer's new program will dramatically decrease costs at the pharmacy counter for the most vulnerable patients, including those who are uninsured or underinsured.
- "Patients have counted on Boehringer Ingelheim for nearly 140 years to tackle challenges across diseases, including respiratory illnesses," said Jean-Michel Boers, President and CEO, Boehringer Ingelheim USA Corporation.
- The company will continue to provide access to free products for eligible patients and comprehensive patient support programs as well.
Retrieved on:
Wednesday, February 14, 2024
BARCELONA, Spain, Feb. 14, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Boehringer Ingelheim has selected Veeva Vault Clinical and Veeva Vault RIM applications as its technology foundation for clinical and regulatory management in its animal health business unit. By adopting unified applications on a single platform, Boehringer Ingelheim can streamline clinical execution to speed development of new medicines that help animals live healthier and happier lives.
Key Points:
- Global animal health leader adopts Veeva Vault Clinical and Veeva Vault RIM for greater efficiency, visibility, and speed
BARCELONA, Spain, Feb. 14, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Boehringer Ingelheim has selected Veeva Vault Clinical and Veeva Vault RIM applications as its technology foundation for clinical and regulatory management in its animal health business unit.
- "Veeva Vault Clinical and Veeva Vault RIM will help us drive higher operational efficiency across functions while providing the insights for data-driven decision making," said Marcus Gravendyck, head of global regulatory affairs and pharmacovigilance, Animal Health at Boehringer Ingelheim.
- The company will also use Vault RIM applications, including Veeva Vault Registrations , Veeva Vault Submissions , and Veeva Vault Submissions Archive for advanced regulatory processes.
- "We're proud to partner with Boehringer Ingelheim in animal health to simplify their clinical development and regulatory processes," said Stefan Jahnecke, vice president of animal health strategy at Veeva.
